Physician profile
Robin C Whitaker
NPI 1477560605
$1,385.72
in general payments reported to CMS, 2019-2025
28 companies · $14.35 in 2025
The $14.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $167 · 2021: $347 · 2022: $122 · 2023: $346 · 2024: $216 · 2025: $14.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.94 |
| Education | $239.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $394.37 | 2019-2022 | |
| Astellas Pharma US INC | $248.00 | 2023 | Veozah |
| Gilead Sciences, INC. | $192.41 | 2024 | |
| Novo Nordisk INC | $60.03 | 2021-2022 | |
| Lilly USA, LLC | $52.63 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $47.55 | 2019-2023 | Trintellix |
| Daiichi Sankyo INC. | $44.53 | 2020-2022 | |
| Organon LLC | $27.27 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $24.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.54 | 2021 | |
| Grifols USA, LLC | $20.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.13 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $17.32 | 2023 | Sunosi |
| Pfizer INC. | $16.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.62 | 2023 | Livalo, Seglentis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.99 | 2021 | |
| Amarin Pharma, INC. | $15.39 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.91 | 2021 | |
| Radius Health, INC. | $14.77 | 2020 | |
| Amgen INC. | $14.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2023 | Xifaxan |
| Abbvie INC. | $14.35 | 2025 | |
| Exeltis, USA INC. | $14.06 | 2024 | Tyblume |
| Horizon Therapeutics Plc | $13.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2019 | |
| Myovant Sciences INC. | $12.06 | 2022 | |
| Allergan, INC. | $11.44 | 2020 | |
| Esperion Therapeutics, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.